Quarterly Result21 May 2026, 07:51 pm
Aurobindo Pharma: FY26 Revenue at ₹111,717.2 Million
AI Summary
Aurobindo Pharma Ltd's board approved the standalone and consolidated audited financial results for the fourth quarter and year ended March 31, 2026. The company reported total revenue from operations of ₹111,717.2 million for FY26. There were changes in auditors: M/s. MRR & Associates resigned as Secretarial Auditor, replaced by M/s. RPR & Associates for a five-year term, subject to shareholder approval. M/s. Ernst & Young LLP were re-appointed as Internal Auditors for June 2026 to May 2027.
Key Highlights
- Aurobindo Pharma's FY26 revenue from operations reached ₹111,717.2 million.
- M/s. MRR & Associates resigned as Secretarial Auditor effective May 22, 2026.
- M/s. RPR & Associates appointed as Secretarial Auditors for five years, pending shareholder approval.
- M/s. Ernst & Young LLP re-appointed as Internal Auditors for June 2026 to May 2027.
- Auditors' reports on financial results have an unmodified opinion.
Price Impact
More from AUROPHARMA